Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02501356 · ClinicalTrials.gov registry record · NA
Effects of ISOThrive on Bodyweight, Body Composition, Hunger/Satiety and Cardiac Risk Measures in Overweight Adults
A NA study, sponsored by Griffin Hospital.
- Completed
- Registry status
- NA
- Development phase
- 103
- Enrollment target
NCT02501356: Completed NA study, sponsored by Griffin Hospital.
NCT02501356 is a NA study that has completed, run by Griffin Hospital. The registered enrollment target is 103 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02501356, a NA study, has completed, sponsored by Griffin Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 103 participants
- Enrollment target
Study Summary
To compare the effects of daily intake of the ISOThrive supplement vs. a placebo on the primary outcome measure of body weight and secondary outcome measures (hunger/satiety, health-related measures and self-reported quality of life) in a group of overweight but otherwise healthy adults.
Primary Outcome
Body weight will be measured at the beginning and at the end of the study using a calibrated digital scale.
Interventions
- DIETARY_SUPPLEMENT Placebo Supplement
- DIETARY_SUPPLEMENT ISOThrive Supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2015-04 |
| Est. Completion | 2015-11 |
| Phase | NA |
What the finished NCT02501356 record still lists
NCT02501356 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo Supplement is the first listed.
NCT02501356 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02501356 about?
NCT02501356 is a clinical study titled "Effects of ISOThrive on Bodyweight, Body Composition, Hunger/Satiety and Cardiac Risk Measures in Overweight Adults". To compare the effects of daily intake of the ISOThrive supplement vs. a placebo on the primary outcome measure of body weight and secondary outcome measures (hunger/satiety, health-related measures and self-reported quality of life) in a group of overweight but otherwise healthy adults.
What is the current status of trial NCT02501356?
This trial is currently completed. It is a NA study. The enrollment target is 103 participants. The study started on 2015-04. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02501356?
The interventions under investigation include: Placebo Supplement (DIETARY_SUPPLEMENT), ISOThrive Supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02501356?
This trial is sponsored by Griffin Hospital, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02501356's enrollment target sits among peer trials
103 837th of 2000 higher than 1,164 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia